Tag Archives: medical device

Hot Investor Mandate: VC Firm Seeks to Invest in Medical Device, Scientific Instrument, and Digital Health Technologies in the Midwest and Southern California

12 Jul

A venture capital firm located in the midwest USA with several offices nationwide. The firm has 3 funds, the third of which they are investing from. The third fund has a vintage year of 2016. The firm currently is looking to make investments from this fund typically in the $.25-1M range with 2x that amount saved for follow on investments. The firm is looking to make 10 investments a year through 2019. The firm typically invests in companies raising Seed Investments, Seed Extensions, or Series A investments. The firm tends to lead 30-40% of their investments and co-invests in the rest. The firm looks at companies primarily in the Midwest, but is also interested in companies in Southern California.

The firm looks for investments primarily in the healthcare IT, medical devices, scientific instruments, and agriculture technology spaces. For the healthcare IT, agriculture technology, and scientific instrument companies, the firm prefers for the companies to have demonstrated product-market fit, some decent revenue traction, and a good revenue trend-line. For the medical device companies, the firm prefers to invest in companies that are just prior to FDA approval or are going through the FDA approval process. The firm’s focus on IT is much broader than just healthcare IT and is willing to consider IT companies beyond the healthcare sector.

The firm looks for companies with experienced management teams. When leading the investments, the firm requests a board seat and when co-investing, the company requests board observer rights if possible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Hong Kong PE Firm Seeks to Invest Up to $10 M in Clinically Validated Medical Device and Diagnostics Products with China Angle

12 Jul

A PE firm that is headquartered in Hong Kong with additional offices throughout China currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

28 Jun

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: